Pharmacyclics Stock Falls On Unusually High Volume (PCYC)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Pharmacyclics Incorporated (Nasdaq: PCYC) is trading at unusually high volume Friday with 3.5 million shares changing hands. It is currently at five times its average daily volume and trading down $2.20 (-2.7%) at $79.47 as of 4 p.m. ET.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Pharmacyclics has a market cap of $5.91 billion and is part of the health care sector and drugs industry. Shares are up 41.3% year to date as of the close of trading on Thursday.

Pharmacyclics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases. The company has a P/E ratio of 73.2, above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Pharmacyclics as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company's earnings per share. You can view the full Pharmacyclics Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

Johnson & Johnson Looks for New Deal That's Just Right

The Nominees for Best Biopharma CEO of 2015 Are...

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

AXON, REGN, BURL, FIVE: Jim Cramer's Views

The 10 Biggest U.S. M&A Deals in 2015